Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction


Cite item

Full Text

Abstract

Aim. To study the influence of long-term of vardenafil use on endothelial and erectile functions in patients with arteriogenic erectile dysfunction (ED)
Subjects and methods. The study included 74 arteriogenic ED patients (mean age 57.4 ± 4.7 years). In addition to a comprehensive andrological examination, all the patients underwent the estimation of the endothelial function of cavernous arteries, the indicator of which is the percentage increase in the diameter of cavernous arteries. The patients were divided into 3 groups: 1) 24 patients receiving vardenafil on demand in a dose of 10 mg; 2) 26 patients taking the drug on demand in a dose of 20 mg; and 3) 24 patients regularly using the agent in a dose of 10 mg every other day. Endothelial and erective functions were re-estimated 1, 3, and 6 months after the initiation of vardenafil therapy and a month following its discontinuation.
Results. Erectile function improvement was noted just a month after the initiation of vardenafil therapy and achieved the maximum values by month 6. The highest erectile function parameters were observed in Group 3. There was a significant endothelial function improvement only in Group 3; the peak effect was achieved by month 6 of treatment.
Conclusion. The long-term use of vardenafil contributes to the improvement of both erectile and endothelial functions in patients with arteriogenic ED.

References

  1. Мазо Е. Б., Гамидов С. И., Иремашвили В. В. К вопросу о патогенезе артериогенной эректильной дисфункии. Врачеб. сословие 2006; 1-2: 4-7.
  2. Малая Л. Т., Корж А. Н., Балковая Л. Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы. Харьков: ТОРСИНГ; 2000.
  3. Vane J., Anggard Е., Botting R. Regulatory function of the vascular endothelium. N. Engl. J. Med. 1990; 323: 27-36.
  4. Иванова О. В., Соболева Г. Н., Карпов Ю. А. Эндотелиальная дисфункция - важный этап развития атеросклеротического поражения сосудов. Тер. арх. 1997; 6: 75-78.
  5. Epstein F. H. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
  6. Камалов А. А., Дорофеев С. Д., Ефремов Е. А. Кардиоваскулярные аспекты эректильной дисфункции. Consilium Medicum 2004; 5:7-10.
  7. Esposito K., Giugliano F., Di Palo C. et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. J. A. M. A. 2004; 291 (24): 2978-2984.
  8. Pourmand G., Alidaee M. R., Rasuli S. et al. Do cigarette smokers with erectile dysfunction benefit from stopping? A prospective study. Br. J. Urol. Int. 2004; 94: 1310-1313.
  9. Carson С. С., Burnett A. L., Levine L. A. et al. The efficacy of Sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60: 12-27.
  10. Francis S. H., Corbin J. D. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. 2003; 4: 457-465.
  11. Saenz de Tejada I., Angulo J., Cellek S. et al. Physiology of erectile function. J. Sex. Med. 2004; 1: 254-265.
  12. Bella A. J., Deyoung L. X., Al-Numi M., Brock G. B. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur. Urol. 2007; 52: 990-1005.
  13. Montorsi F., Briganti A., Salonia A. et al. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur. Urol. 2006; 49: 979-986.
  14. McMahon C. G. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur. Urol. 2006; 50: 215-217.
  15. McMahon C. G. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J. Sex. Med. 2005; 2: 415-425.
  16. Porst H., Giuliano F., Glina S. et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo controlled trial. Eur. Urol. 2006; 50: 351-359.
  17. Mirone V., Costa P., Damber J. E. et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur. Urol. 2005; 47: 846-854.
  18. Buvat J., Faria G., Wetterauer U. et al. Tadalafil 5mg and 10 mg taken once a day for the treatment of erectile dysfunction improves patient sexual satisfaction. J. Sex. Med. 2007; 4 (suppl. 1): 91, abstr. no. 84.
  19. Mazo E. B., Gamidov S. I., Iremashvili V. V. Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernous arteries? A pilot study. Br. J. Urol. Int. 2006; 98: 1054-1058.
  20. McMahon C. G. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to ondemand tadalafil. J. Sex. Med. 2004; 1: 292-300.
  21. Hatzimouratidis K., Moysidis K., Bekos A. et al. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur. Urol. 2006; 50: 126-133.
  22. Montorsi F., Briganti A., Salonia A. et al. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur. Urol. 2006; 49: 979-986.
  23. Sommer F., Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. Wld. J. Urol. 2005; 23: 385-392.
  24. Иремашвили В. В. Значение исследования эндотелиальной функции у больных эректильной дисфункцией: Дис. ... канд. мед. наук. - М., 2006.
  25. Desouza C., Parulkar A., Lumpkin D. et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabet. Care 2002; 25: 1336-1339.
  26. Katz S. D., Balidemaj K., Homma S. et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. 2000; 36: 845-851.
  27. Kimura M., Higashi Y., Hara K. et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41: 1106-1110.
  28. Park J. W., Mrowietz C., Chung N., Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. Clin. Hemorheol. Microcirc. 2004; 31: 173-183.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies